| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 98 | 2020 | 263 | 19.670 |
Why?
|
| Hyperthermia, Induced | 86 | 2020 | 241 | 14.800 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 56 | 2020 | 155 | 9.840 |
Why?
|
| Appendiceal Neoplasms | 32 | 2020 | 98 | 9.020 |
Why?
|
| Adenocarcinoma | 48 | 2019 | 300 | 6.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 49 | 2020 | 456 | 6.370 |
Why?
|
| Combined Modality Therapy | 85 | 2020 | 563 | 4.610 |
Why?
|
| Breast Neoplasms | 45 | 2021 | 754 | 4.590 |
Why?
|
| Antineoplastic Agents | 31 | 2020 | 599 | 4.490 |
Why?
|
| Stomach Neoplasms | 29 | 2019 | 113 | 4.120 |
Why?
|
| Sentinel Lymph Node Biopsy | 24 | 2020 | 71 | 3.910 |
Why?
|
| Survival Rate | 81 | 2020 | 894 | 3.620 |
Why?
|
| Colorectal Neoplasms | 22 | 2020 | 222 | 3.570 |
Why?
|
| Neoplasm Staging | 69 | 2021 | 470 | 3.350 |
Why?
|
| Middle Aged | 189 | 2021 | 12125 | 3.300 |
Why?
|
| Neoplasm Recurrence, Local | 32 | 2020 | 384 | 3.240 |
Why?
|
| Humans | 267 | 2021 | 32798 | 3.010 |
Why?
|
| Mitomycin | 21 | 2020 | 51 | 2.960 |
Why?
|
| Carcinoma | 16 | 2016 | 92 | 2.960 |
Why?
|
| Female | 210 | 2021 | 20261 | 2.920 |
Why?
|
| Adult | 139 | 2021 | 9560 | 2.840 |
Why?
|
| Melanoma | 14 | 2019 | 165 | 2.810 |
Why?
|
| Aged | 144 | 2021 | 10538 | 2.740 |
Why?
|
| Prognosis | 71 | 2020 | 1544 | 2.580 |
Why?
|
| Adenocarcinoma, Mucinous | 6 | 2020 | 28 | 2.540 |
Why?
|
| Quality of Life | 15 | 2020 | 961 | 2.510 |
Why?
|
| Retrospective Studies | 98 | 2020 | 3701 | 2.450 |
Why?
|
| Male | 163 | 2020 | 19641 | 2.450 |
Why?
|
| Postoperative Complications | 26 | 2018 | 828 | 2.310 |
Why?
|
| Skin Neoplasms | 11 | 2019 | 217 | 2.170 |
Why?
|
| Follow-Up Studies | 66 | 2021 | 2284 | 2.160 |
Why?
|
| Treatment Outcome | 68 | 2021 | 3438 | 2.140 |
Why?
|
| Aged, 80 and over | 71 | 2021 | 4032 | 2.030 |
Why?
|
| Adrenocortical Carcinoma | 16 | 2019 | 35 | 2.010 |
Why?
|
| Adrenal Cortex Neoplasms | 16 | 2019 | 36 | 2.010 |
Why?
|
| Lymph Nodes | 14 | 2019 | 114 | 1.960 |
Why?
|
| Colonic Neoplasms | 9 | 2016 | 74 | 1.870 |
Why?
|
| Chemotherapy, Adjuvant | 31 | 2019 | 205 | 1.830 |
Why?
|
| Prospective Studies | 44 | 2021 | 2327 | 1.800 |
Why?
|
| Mesothelioma | 10 | 2019 | 39 | 1.780 |
Why?
|
| Gastrectomy | 22 | 2018 | 70 | 1.750 |
Why?
|
| Liver Neoplasms | 12 | 2018 | 154 | 1.590 |
Why?
|
| Neoplasms | 14 | 2020 | 761 | 1.570 |
Why?
|
| Peritoneum | 8 | 2020 | 33 | 1.570 |
Why?
|
| Mastectomy | 14 | 2020 | 61 | 1.570 |
Why?
|
| Esophageal Neoplasms | 6 | 2014 | 39 | 1.540 |
Why?
|
| Infusions, Parenteral | 22 | 2016 | 65 | 1.520 |
Why?
|
| Lymphatic Metastasis | 29 | 2020 | 169 | 1.450 |
Why?
|
| Lymph Node Excision | 18 | 2019 | 95 | 1.400 |
Why?
|
| Radiopharmaceuticals | 9 | 2010 | 92 | 1.170 |
Why?
|
| Radiography, Thoracic | 2 | 2019 | 44 | 1.170 |
Why?
|
| Pseudomyxoma Peritonei | 7 | 2014 | 12 | 1.170 |
Why?
|
| Young Adult | 31 | 2020 | 2730 | 1.160 |
Why?
|
| Mammaplasty | 6 | 2013 | 26 | 0.980 |
Why?
|
| Antibiotics, Antineoplastic | 8 | 2011 | 69 | 0.960 |
Why?
|
| Fluorodeoxyglucose F18 | 7 | 2010 | 51 | 0.950 |
Why?
|
| Survival Analysis | 30 | 2017 | 486 | 0.940 |
Why?
|
| Sarcoma | 6 | 2020 | 71 | 0.880 |
Why?
|
| Organoplatinum Compounds | 5 | 2013 | 46 | 0.870 |
Why?
|
| Jejunal Neoplasms | 3 | 2013 | 6 | 0.860 |
Why?
|
| Rectal Neoplasms | 4 | 2013 | 21 | 0.860 |
Why?
|
| Adrenalectomy | 8 | 2018 | 30 | 0.830 |
Why?
|
| Disease-Free Survival | 22 | 2018 | 326 | 0.780 |
Why?
|
| Positron-Emission Tomography | 6 | 2010 | 167 | 0.780 |
Why?
|
| Predictive Value of Tests | 14 | 2019 | 887 | 0.760 |
Why?
|
| Mastectomy, Segmental | 7 | 2021 | 27 | 0.760 |
Why?
|
| Duodenal Neoplasms | 2 | 2013 | 6 | 0.750 |
Why?
|
| Blood Cell Count | 2 | 2019 | 27 | 0.730 |
Why?
|
| Morbidity | 10 | 2017 | 101 | 0.720 |
Why?
|
| Mutation | 6 | 2017 | 493 | 0.710 |
Why?
|
| Neoadjuvant Therapy | 6 | 2019 | 66 | 0.700 |
Why?
|
| Carcinoma, Lobular | 4 | 2015 | 12 | 0.690 |
Why?
|
| Neoplasm Invasiveness | 12 | 2017 | 193 | 0.670 |
Why?
|
| Abdominal Neoplasms | 3 | 2014 | 13 | 0.650 |
Why?
|
| Surgical Wound Infection | 3 | 2019 | 98 | 0.650 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2019 | 35 | 0.650 |
Why?
|
| Ileal Neoplasms | 2 | 2013 | 4 | 0.640 |
Why?
|
| Depression | 4 | 2020 | 448 | 0.640 |
Why?
|
| Pancreatectomy | 5 | 2019 | 25 | 0.630 |
Why?
|
| Ovarian Neoplasms | 5 | 2016 | 103 | 0.630 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 316 | 0.620 |
Why?
|
| Hepatectomy | 7 | 2018 | 56 | 0.610 |
Why?
|
| Gynecology | 1 | 2019 | 20 | 0.610 |
Why?
|
| Obstetrics | 1 | 2019 | 28 | 0.600 |
Why?
|
| Workplace | 1 | 2019 | 50 | 0.600 |
Why?
|
| Proportional Hazards Models | 14 | 2020 | 764 | 0.600 |
Why?
|
| Liver Function Tests | 1 | 2019 | 22 | 0.600 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 881 | 0.590 |
Why?
|
| Pancreatic Neoplasms | 6 | 2019 | 129 | 0.590 |
Why?
|
| Esophagectomy | 4 | 2014 | 17 | 0.580 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2009 | 9 | 0.580 |
Why?
|
| Burnout, Professional | 1 | 2019 | 53 | 0.580 |
Why?
|
| Adolescent | 21 | 2018 | 3638 | 0.580 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2020 | 19 | 0.570 |
Why?
|
| Caregivers | 1 | 2020 | 121 | 0.570 |
Why?
|
| Rosaniline Dyes | 6 | 2009 | 18 | 0.560 |
Why?
|
| United States | 32 | 2019 | 4108 | 0.560 |
Why?
|
| Carcinoma, Ductal, Breast | 5 | 2020 | 30 | 0.550 |
Why?
|
| Enteral Nutrition | 2 | 2015 | 28 | 0.550 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2016 | 12 | 0.530 |
Why?
|
| Retroperitoneal Neoplasms | 3 | 2019 | 18 | 0.520 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 3 | 0.520 |
Why?
|
| Laparotomy | 1 | 2017 | 30 | 0.510 |
Why?
|
| Cohort Studies | 14 | 2018 | 1844 | 0.510 |
Why?
|
| Coloring Agents | 4 | 2009 | 30 | 0.510 |
Why?
|
| Sensitivity and Specificity | 13 | 2018 | 576 | 0.500 |
Why?
|
| Carboplatin | 4 | 2013 | 51 | 0.490 |
Why?
|
| Length of Stay | 8 | 2019 | 329 | 0.470 |
Why?
|
| Leiomyosarcoma | 3 | 2010 | 10 | 0.440 |
Why?
|
| Intraoperative Care | 7 | 2015 | 48 | 0.440 |
Why?
|
| Genetic Testing | 2 | 2013 | 99 | 0.440 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 38 | 0.430 |
Why?
|
| Thalidomide | 1 | 2014 | 30 | 0.430 |
Why?
|
| Radiotherapy, Adjuvant | 13 | 2019 | 80 | 0.430 |
Why?
|
| Registries | 9 | 2018 | 315 | 0.420 |
Why?
|
| Cytological Techniques | 2 | 2011 | 17 | 0.420 |
Why?
|
| Multivariate Analysis | 10 | 2016 | 682 | 0.420 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 192 | 0.410 |
Why?
|
| Adjuvants, Immunologic | 2 | 2011 | 54 | 0.400 |
Why?
|
| Breast Diseases | 1 | 2013 | 3 | 0.400 |
Why?
|
| Nipples | 1 | 2013 | 3 | 0.400 |
Why?
|
| Databases, Factual | 11 | 2018 | 369 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2009 | 264 | 0.390 |
Why?
|
| Health Status | 5 | 2019 | 402 | 0.380 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2019 | 22 | 0.380 |
Why?
|
| Intraoperative Period | 6 | 2011 | 43 | 0.370 |
Why?
|
| BCG Vaccine | 1 | 2011 | 7 | 0.360 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2011 | 2 | 0.360 |
Why?
|
| Biopsy, Needle | 4 | 2005 | 90 | 0.360 |
Why?
|
| Breast | 2 | 2020 | 64 | 0.360 |
Why?
|
| Genes, BRCA2 | 2 | 2011 | 10 | 0.360 |
Why?
|
| Cisplatin | 6 | 2014 | 81 | 0.350 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2011 | 6 | 0.350 |
Why?
|
| Secondary Prevention | 1 | 2011 | 65 | 0.350 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 428 | 0.340 |
Why?
|
| Societies, Medical | 2 | 2016 | 163 | 0.340 |
Why?
|
| Adenoma | 1 | 2011 | 35 | 0.340 |
Why?
|
| Biopsy | 3 | 2020 | 245 | 0.330 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2010 | 2 | 0.330 |
Why?
|
| Incidence | 9 | 2019 | 1238 | 0.330 |
Why?
|
| Medical Oncology | 1 | 2011 | 92 | 0.330 |
Why?
|
| Thoracoscopy | 1 | 2010 | 12 | 0.330 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2009 | 5 | 0.320 |
Why?
|
| Organoids | 3 | 2020 | 98 | 0.320 |
Why?
|
| Nutrition Assessment | 2 | 2014 | 54 | 0.310 |
Why?
|
| Colectomy | 3 | 2014 | 30 | 0.310 |
Why?
|
| Mammography | 4 | 2005 | 40 | 0.310 |
Why?
|
| Tomography, Emission-Computed | 3 | 2005 | 22 | 0.310 |
Why?
|
| Subcutaneous Tissue | 1 | 2009 | 6 | 0.300 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2009 | 2 | 0.300 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2019 | 55 | 0.300 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2019 | 24 | 0.300 |
Why?
|
| Disease Progression | 7 | 2017 | 594 | 0.300 |
Why?
|
| Uterine Neoplasms | 1 | 2009 | 29 | 0.300 |
Why?
|
| Disease Management | 2 | 2020 | 128 | 0.290 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 19 | 0.290 |
Why?
|
| Yoga | 1 | 2009 | 52 | 0.280 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2011 | 4 | 0.280 |
Why?
|
| Risk Factors | 13 | 2017 | 3974 | 0.280 |
Why?
|
| Pleural Neoplasms | 2 | 2007 | 11 | 0.280 |
Why?
|
| Fertility Agents, Female | 1 | 2007 | 5 | 0.270 |
Why?
|
| Frozen Sections | 4 | 2014 | 18 | 0.270 |
Why?
|
| Leuprolide | 1 | 2007 | 5 | 0.270 |
Why?
|
| Breast Neoplasms, Male | 1 | 2007 | 11 | 0.270 |
Why?
|
| Neoplasm Metastasis | 9 | 2019 | 220 | 0.270 |
Why?
|
| Microwaves | 1 | 2007 | 8 | 0.270 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2007 | 52 | 0.270 |
Why?
|
| Electrocoagulation | 1 | 2007 | 12 | 0.260 |
Why?
|
| Catheter Ablation | 3 | 2004 | 114 | 0.260 |
Why?
|
| Polymorphism, Genetic | 4 | 2011 | 183 | 0.260 |
Why?
|
| Deoxycytidine | 5 | 2013 | 63 | 0.260 |
Why?
|
| Models, Biological | 2 | 2019 | 392 | 0.260 |
Why?
|
| Mental Health | 2 | 2019 | 128 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2012 | 157 | 0.260 |
Why?
|
| Pilot Projects | 7 | 2019 | 565 | 0.250 |
Why?
|
| Logistic Models | 7 | 2018 | 783 | 0.250 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2006 | 3 | 0.250 |
Why?
|
| Hemoperitoneum | 1 | 2006 | 4 | 0.250 |
Why?
|
| Patient Readmission | 3 | 2016 | 134 | 0.250 |
Why?
|
| Activities of Daily Living | 4 | 2011 | 258 | 0.250 |
Why?
|
| Child | 7 | 2014 | 2478 | 0.240 |
Why?
|
| Blood Transfusion | 2 | 2017 | 76 | 0.240 |
Why?
|
| Obesity | 1 | 2013 | 1152 | 0.240 |
Why?
|
| Feasibility Studies | 6 | 2019 | 308 | 0.240 |
Why?
|
| European Continental Ancestry Group | 4 | 2017 | 1163 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 133 | 0.240 |
Why?
|
| Reproducibility of Results | 6 | 2020 | 767 | 0.240 |
Why?
|
| DNA Repair | 4 | 2014 | 57 | 0.230 |
Why?
|
| Nomograms | 2 | 2016 | 35 | 0.230 |
Why?
|
| Preoperative Care | 3 | 2013 | 122 | 0.230 |
Why?
|
| Jejunostomy | 2 | 2015 | 7 | 0.230 |
Why?
|
| North Carolina | 8 | 2015 | 1546 | 0.230 |
Why?
|
| Receptor, erbB-2 | 2 | 2014 | 65 | 0.230 |
Why?
|
| Gallbladder Neoplasms | 2 | 2015 | 34 | 0.220 |
Why?
|
| Intussusception | 1 | 2004 | 2 | 0.220 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2004 | 2 | 0.220 |
Why?
|
| Colonoscopy | 2 | 2019 | 45 | 0.220 |
Why?
|
| Reoperation | 5 | 2017 | 260 | 0.210 |
Why?
|
| Genetic Markers | 2 | 2015 | 125 | 0.210 |
Why?
|
| Cluster Analysis | 2 | 2015 | 126 | 0.210 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 6 | 0.210 |
Why?
|
| Blood Platelets | 2 | 2015 | 40 | 0.210 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 476 | 0.210 |
Why?
|
| Ethnic Groups | 3 | 2016 | 474 | 0.210 |
Why?
|
| Age Factors | 8 | 2017 | 1197 | 0.210 |
Why?
|
| Parathyroid Neoplasms | 1 | 2003 | 7 | 0.200 |
Why?
|
| Vascular Surgical Procedures | 3 | 2015 | 92 | 0.200 |
Why?
|
| Time Factors | 8 | 2020 | 2183 | 0.200 |
Why?
|
| Neutrophils | 2 | 2015 | 110 | 0.200 |
Why?
|
| Camptothecin | 2 | 2005 | 48 | 0.200 |
Why?
|
| Surgical Flaps | 3 | 2013 | 77 | 0.200 |
Why?
|
| Patient Selection | 4 | 2020 | 281 | 0.190 |
Why?
|
| Interferon-alpha | 1 | 2003 | 70 | 0.190 |
Why?
|
| Genes, p53 | 3 | 2017 | 23 | 0.190 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 54 | 0.190 |
Why?
|
| Cytodiagnosis | 3 | 2011 | 15 | 0.190 |
Why?
|
| Pregnancy | 3 | 2019 | 981 | 0.190 |
Why?
|
| Clinical Trials as Topic | 3 | 2009 | 307 | 0.190 |
Why?
|
| Injections, Intraperitoneal | 5 | 2014 | 47 | 0.180 |
Why?
|
| Lymphocytes | 2 | 2015 | 59 | 0.180 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 526 | 0.180 |
Why?
|
| Health Services Accessibility | 3 | 2019 | 252 | 0.180 |
Why?
|
| Hospital Mortality | 3 | 2017 | 205 | 0.170 |
Why?
|
| Consensus | 2 | 2013 | 87 | 0.170 |
Why?
|
| GTP Phosphohydrolases | 1 | 2020 | 9 | 0.170 |
Why?
|
| Anus Neoplasms | 2 | 2012 | 13 | 0.170 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 18 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 13 | 0.160 |
Why?
|
| Extremities | 1 | 2020 | 54 | 0.160 |
Why?
|
| Precancerous Conditions | 1 | 2020 | 25 | 0.160 |
Why?
|
| Pelvis | 2 | 2018 | 64 | 0.160 |
Why?
|
| Necrosis | 2 | 2013 | 51 | 0.160 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 72 | 0.160 |
Why?
|
| Health Care Rationing | 1 | 2020 | 12 | 0.160 |
Why?
|
| Immune System Phenomena | 1 | 2020 | 5 | 0.160 |
Why?
|
| Oncogenes | 1 | 2020 | 14 | 0.160 |
Why?
|
| Radiotherapy Dosage | 4 | 2010 | 99 | 0.160 |
Why?
|
| Remote Consultation | 1 | 2019 | 12 | 0.160 |
Why?
|
| Cost of Illness | 1 | 2020 | 71 | 0.160 |
Why?
|
| Hospitals, University | 1 | 2019 | 31 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2013 | 532 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2020 | 147 | 0.160 |
Why?
|
| Peritoneal Lavage | 1 | 2019 | 1 | 0.160 |
Why?
|
| Splenectomy | 3 | 2017 | 22 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 59 | 0.160 |
Why?
|
| Immunohistochemistry | 4 | 2008 | 497 | 0.150 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 36 | 0.150 |
Why?
|
| Leadership | 1 | 2019 | 40 | 0.150 |
Why?
|
| Odds Ratio | 7 | 2015 | 467 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 1 | 2019 | 10 | 0.150 |
Why?
|
| Seroma | 1 | 2019 | 5 | 0.150 |
Why?
|
| Self Efficacy | 1 | 2019 | 81 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2015 | 43 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2019 | 39 | 0.150 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 3 | 0.150 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2019 | 13 | 0.150 |
Why?
|
| Laparoscopy | 2 | 2019 | 184 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 22 | 0.150 |
Why?
|
| Membrane Proteins | 1 | 2020 | 251 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2018 | 602 | 0.140 |
Why?
|
| Vascular Neoplasms | 2 | 2010 | 12 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 98 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 102 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2011 | 21 | 0.140 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 1 | 0.140 |
Why?
|
| Vena Cava, Inferior | 2 | 2010 | 30 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 412 | 0.140 |
Why?
|
| Urachus | 1 | 2017 | 3 | 0.140 |
Why?
|
| Intensive Care Units | 2 | 2015 | 115 | 0.140 |
Why?
|
| Appendectomy | 1 | 2018 | 19 | 0.140 |
Why?
|
| Anesthesia, Conduction | 1 | 2018 | 24 | 0.140 |
Why?
|
| Skin Diseases | 1 | 2019 | 145 | 0.140 |
Why?
|
| Dermatology | 1 | 2019 | 163 | 0.130 |
Why?
|
| Diaphragm | 2 | 2014 | 38 | 0.130 |
Why?
|
| Risk Assessment | 7 | 2017 | 1460 | 0.130 |
Why?
|
| Animals | 5 | 2019 | 7569 | 0.130 |
Why?
|
| Hospital Charges | 1 | 2017 | 16 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 22 | 0.130 |
Why?
|
| Crohn Disease | 1 | 2017 | 29 | 0.130 |
Why?
|
| Medicaid | 2 | 2008 | 99 | 0.130 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 10 | 0.130 |
Why?
|
| Cross Infection | 1 | 2017 | 56 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 133 | 0.130 |
Why?
|
| Lymphedema | 2 | 2017 | 4 | 0.130 |
Why?
|
| Vomiting | 2 | 2014 | 22 | 0.120 |
Why?
|
| African Americans | 3 | 2017 | 1424 | 0.120 |
Why?
|
| Emotions | 1 | 2016 | 59 | 0.120 |
Why?
|
| Nausea | 2 | 2014 | 52 | 0.120 |
Why?
|
| Taxoids | 2 | 2013 | 55 | 0.120 |
Why?
|
| Mitotane | 1 | 2015 | 2 | 0.120 |
Why?
|
| Gastric Stump | 1 | 2015 | 2 | 0.120 |
Why?
|
| Linitis Plastica | 1 | 2015 | 2 | 0.120 |
Why?
|
| Gastroenterostomy | 1 | 2015 | 2 | 0.120 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2015 | 6 | 0.120 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2015 | 7 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 835 | 0.120 |
Why?
|
| Peritoneal Stomata | 1 | 2015 | 3 | 0.120 |
Why?
|
| Bile Ducts | 1 | 2015 | 20 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 32 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 160 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 143 | 0.120 |
Why?
|
| Patient Admission | 1 | 2015 | 59 | 0.120 |
Why?
|
| Blood Vessels | 1 | 2015 | 51 | 0.110 |
Why?
|
| Anemia | 1 | 2015 | 57 | 0.110 |
Why?
|
| Pain Measurement | 1 | 2016 | 356 | 0.110 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2014 | 6 | 0.110 |
Why?
|
| Skilled Nursing Facilities | 1 | 2014 | 12 | 0.110 |
Why?
|
| Anastomosis, Surgical | 2 | 2015 | 57 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 289 | 0.110 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 12 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 38 | 0.110 |
Why?
|
| Abdominal Cavity | 1 | 2014 | 5 | 0.110 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 483 | 0.110 |
Why?
|
| Gastrostomy | 1 | 2014 | 16 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 32 | 0.110 |
Why?
|
| Appendix | 1 | 2014 | 4 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2014 | 38 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 41 | 0.110 |
Why?
|
| Neoplasm, Residual | 3 | 2016 | 25 | 0.110 |
Why?
|
| Thiosulfates | 1 | 2013 | 3 | 0.110 |
Why?
|
| Axilla | 3 | 2020 | 17 | 0.100 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2015 | 198 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2013 | 23 | 0.100 |
Why?
|
| Ascites | 1 | 2013 | 15 | 0.100 |
Why?
|
| Urinary Tract | 1 | 2013 | 22 | 0.100 |
Why?
|
| Urologic Diseases | 1 | 2013 | 27 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 29 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2014 | 204 | 0.100 |
Why?
|
| BRCA2 Protein | 1 | 2013 | 3 | 0.100 |
Why?
|
| BRCA1 Protein | 1 | 2013 | 6 | 0.100 |
Why?
|
| Tumor Burden | 3 | 2017 | 60 | 0.100 |
Why?
|
| Genotype | 2 | 2012 | 731 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 1572 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2013 | 99 | 0.100 |
Why?
|
| Genomics | 1 | 2013 | 88 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 2 | 2012 | 60 | 0.090 |
Why?
|
| Anthracyclines | 1 | 2013 | 52 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 1066 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2016 | 908 | 0.090 |
Why?
|
| Tissue Expansion Devices | 1 | 2011 | 10 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2011 | 6 | 0.090 |
Why?
|
| Diet | 1 | 2014 | 390 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 215 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 30 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2014 | 338 | 0.090 |
Why?
|
| Chi-Square Distribution | 3 | 2009 | 292 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 43 | 0.090 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 8 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 154 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 1307 | 0.090 |
Why?
|
| Heterozygote | 1 | 2011 | 61 | 0.090 |
Why?
|
| Case-Control Studies | 5 | 2014 | 876 | 0.090 |
Why?
|
| Sleep | 1 | 2012 | 89 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 422 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 10 | 0.090 |
Why?
|
| Pancreatitis | 1 | 2011 | 18 | 0.090 |
Why?
|
| Organizational Objectives | 1 | 2010 | 23 | 0.080 |
Why?
|
| Poverty | 2 | 2008 | 116 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 83 | 0.080 |
Why?
|
| Phenotype | 1 | 2012 | 638 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 240 | 0.080 |
Why?
|
| Research Design | 1 | 2012 | 331 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 947 | 0.080 |
Why?
|
| Smoking | 2 | 2017 | 531 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 194 | 0.080 |
Why?
|
| Fluorouracil | 4 | 2012 | 82 | 0.080 |
Why?
|
| Equipment Design | 2 | 2007 | 179 | 0.080 |
Why?
|
| Medical Records | 4 | 2012 | 77 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 38 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2019 | 94 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2009 | 49 | 0.070 |
Why?
|
| Multifactorial Inheritance | 1 | 2008 | 22 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2008 | 2 | 0.070 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 4 | 0.070 |
Why?
|
| Glutathione Transferase | 1 | 2008 | 12 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2008 | 94 | 0.070 |
Why?
|
| Telomere | 1 | 2008 | 11 | 0.070 |
Why?
|
| Comorbidity | 3 | 2017 | 573 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2008 | 24 | 0.070 |
Why?
|
| Ascitic Fluid | 1 | 2007 | 5 | 0.070 |
Why?
|
| Perfusion | 2 | 2020 | 74 | 0.070 |
Why?
|
| Leg | 1 | 2007 | 64 | 0.070 |
Why?
|
| Paclitaxel | 3 | 2013 | 67 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2008 | 78 | 0.070 |
Why?
|
| Neck | 1 | 2007 | 31 | 0.070 |
Why?
|
| Neoplasm Proteins | 3 | 2017 | 145 | 0.070 |
Why?
|
| NAD | 1 | 2007 | 27 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 23 | 0.070 |
Why?
|
| Cell Death | 1 | 2007 | 71 | 0.070 |
Why?
|
| Health Surveys | 1 | 2007 | 200 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 135 | 0.070 |
Why?
|
| Neutropenia | 2 | 2008 | 27 | 0.060 |
Why?
|
| Health Promotion | 1 | 2009 | 255 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2006 | 8 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2006 | 20 | 0.060 |
Why?
|
| Patient Participation | 1 | 2007 | 87 | 0.060 |
Why?
|
| Keratins | 1 | 2006 | 37 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 622 | 0.060 |
Why?
|
| Rupture | 1 | 2006 | 34 | 0.060 |
Why?
|
| Exercise | 1 | 2011 | 679 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 47 | 0.060 |
Why?
|
| Telomerase | 1 | 2006 | 20 | 0.060 |
Why?
|
| Survival | 1 | 2006 | 12 | 0.060 |
Why?
|
| Continental Population Groups | 1 | 2007 | 236 | 0.060 |
Why?
|
| Endosonography | 1 | 2006 | 53 | 0.060 |
Why?
|
| Suture Techniques | 1 | 2006 | 61 | 0.060 |
Why?
|
| International Agencies | 2 | 2017 | 10 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 271 | 0.050 |
Why?
|
| Hemangioma, Cavernous | 1 | 2004 | 3 | 0.050 |
Why?
|
| Nevus | 1 | 2004 | 15 | 0.050 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 2003 | 1 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2003 | 10 | 0.050 |
Why?
|
| Anoikis | 1 | 2003 | 2 | 0.050 |
Why?
|
| Tropomyosin | 1 | 2003 | 3 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 42 | 0.050 |
Why?
|
| Monitoring, Intraoperative | 1 | 2004 | 44 | 0.050 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2003 | 13 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2003 | 39 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2004 | 288 | 0.050 |
Why?
|
| Hypercalcemia | 1 | 2003 | 11 | 0.050 |
Why?
|
| Preoperative Period | 2 | 2014 | 34 | 0.050 |
Why?
|
| Massage | 1 | 2003 | 12 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2003 | 186 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2003 | 45 | 0.050 |
Why?
|
| Cell Biology | 1 | 2002 | 2 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2002 | 31 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 247 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2002 | 57 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 199 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 225 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 71 | 0.040 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 12 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 29 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 22 | 0.040 |
Why?
|
| Ohio | 1 | 2019 | 64 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 40 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 21 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2019 | 10 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 10 | 0.040 |
Why?
|
| Remission Induction | 2 | 2010 | 86 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2019 | 11 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 48 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 75 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 78 | 0.040 |
Why?
|
| Pancreatic Diseases | 1 | 2019 | 19 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 181 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 49 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2011 | 195 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 238 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 436 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 280 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2018 | 40 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 168 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 15 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 28 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 14 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 35 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 17 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2011 | 142 | 0.030 |
Why?
|
| Genes, ras | 1 | 2017 | 25 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 178 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 78 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 84 | 0.030 |
Why?
|
| Diarrhea | 2 | 2008 | 58 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 98 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2017 | 116 | 0.030 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 4 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 99 | 0.030 |
Why?
|
| Abdomen | 1 | 2016 | 46 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 16 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2015 | 11 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 488 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2015 | 57 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 23 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 24 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2015 | 26 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2019 | 686 | 0.030 |
Why?
|
| Stomach | 1 | 2015 | 17 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2015 | 48 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 54 | 0.030 |
Why?
|
| Colon | 1 | 2015 | 51 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 240 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 85 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2017 | 381 | 0.030 |
Why?
|
| Pancreas | 1 | 2015 | 103 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 459 | 0.030 |
Why?
|
| beta Carotene | 1 | 2014 | 6 | 0.030 |
Why?
|
| Folic Acid Deficiency | 1 | 2014 | 2 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 10 | 0.030 |
Why?
|
| Folic Acid | 1 | 2014 | 11 | 0.030 |
Why?
|
| Malnutrition | 1 | 2014 | 19 | 0.030 |
Why?
|
| Pneumonia | 1 | 2014 | 64 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 57 | 0.030 |
Why?
|
| Omentum | 1 | 2014 | 25 | 0.030 |
Why?
|
| Micronutrients | 1 | 2014 | 20 | 0.030 |
Why?
|
| Thrombosis | 1 | 2014 | 81 | 0.030 |
Why?
|
| Zinc | 1 | 2014 | 31 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1002 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 106 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 59 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 101 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 162 | 0.030 |
Why?
|
| Energy Intake | 1 | 2014 | 128 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 2511 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 41 | 0.030 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2013 | 1 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2013 | 15 | 0.030 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2013 | 4 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2013 | 26 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 19 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2013 | 83 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 492 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 112 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 2012 | 29 | 0.020 |
Why?
|
| Physician's Role | 1 | 2012 | 39 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 83 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 111 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 67 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 56 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 76 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 726 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2010 | 3 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 218 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 138 | 0.020 |
Why?
|
| Temperature | 1 | 2010 | 51 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 265 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 675 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2008 | 14 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2008 | 6 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 97 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 82 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 89 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2008 | 84 | 0.020 |
Why?
|
| Patient Care | 1 | 2008 | 30 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 157 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 148 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 189 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 253 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 29 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 247 | 0.020 |
Why?
|
| SEER Program | 1 | 2007 | 33 | 0.020 |
Why?
|
| Gender Identity | 1 | 2007 | 28 | 0.020 |
Why?
|
| Leucovorin | 1 | 2007 | 23 | 0.020 |
Why?
|
| Drainage | 1 | 2007 | 64 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 185 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 201 | 0.020 |
Why?
|
| Observer Variation | 1 | 2006 | 96 | 0.020 |
Why?
|
| Vacuum | 1 | 2006 | 22 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 28 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 41 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 83 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 68 | 0.010 |
Why?
|
| Wound Healing | 1 | 2006 | 188 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2004 | 18 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 10 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 39 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 59 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 34 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 2003 | 23 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 59 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2004 | 58 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 70 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 134 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2003 | 78 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2002 | 59 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 498 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 475 | 0.010 |
Why?
|